Related Experiment Video

Updated: Feb 1, 2026

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
07:12

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Published on: July 7, 2016

21.0K

[Progress of Auto-HSCT for Treatment of DLBCL--Review]

Xi Wang1, Bing Xia1, Yi-Zhuo Zhang2

  • 1Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Tianjin Municipal Key Laboratory of Cancer Prevention and Therapy，Tianjin Municipal Clinical Research Center for Cancer，Tianjin 300060，China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|December 4, 2018
PubMed

Insights

Autologous hematopoietic stem cell transplantation is a key treatment for high-risk or relapsed Diffuse Large B-cell Lymphoma (DLBCL). Research confirms its effectiveness and explores methods to further improve outcomes for DLBCL patients.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse Large B-cell Lymphoma (DLBCL) is the most prevalent adult non-Hodgkin's lymphoma, representing 30-40% of cases.
  • Current treatments include chemotherapy, radiotherapy, and autologous hematopoietic stem cell transplantation (aHSCT).

Purpose of the Study:

  • To evaluate the effectiveness of aHSCT as a primary treatment for high-risk young and relapsed/refractory DLBCL patients.
  • To explore strategies for enhancing the efficacy of aHSCT in DLBCL management.

Main Methods:

  • Systematic review and meta-analysis of existing studies on aHSCT for DLBCL.
  • Comparative analysis of treatment outcomes based on patient risk stratification and disease status.

Main Results:

  • aHSCT is identified as a primary treatment approach for specific DLBCL patient groups.
  • Studies indicate that aHSCT demonstrates significant advantages for DLBCL patients, particularly those with high-risk or relapsed/refractory disease.
  • Ongoing research aims to optimize aHSCT protocols to improve patient outcomes.

Conclusions:

  • Autologous hematopoietic stem cell transplantation is a crucial therapeutic option for selected Diffuse Large B-cell Lymphoma patients.
  • Further research into improving transplantation techniques is warranted to maximize benefits for DLBCL patients.

More Related Videos

Evaluating Skilled Prehension in Mice Using an Auto-Trainer05:01

Evaluating Skilled Prehension in Mice Using an Auto-Trainer

Published on: September 12, 2019

6.0K
Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector05:06

Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector

Published on: February 2, 2021

2.7K

Related Concept Videos

Review and Preview01:10

Review and Preview

In statistics, several tools are used to interpret the data. Measures of central tendency represent the characteristics of the data, such as mean, median, and mode. Additionally, measures of variance like standard deviation and range are used to find the spread of data from the mean. Relative standing measures the distance between data locations. Commonly used measures of relative standings are percentile, z score, and quartiles.
Percentiles are a type of fractile that partition data into...
8.4K
Review and Preview01:13

Review and Preview

Data are individual items of information obtained from a population or sample. Data may be classified as qualitative (categorical), quantitative continuous, or quantitative discrete. Because it is not practical to measure the entire population in a study, researchers use samples to represent the population. A random sample is a representative group from the population chosen by using a method that gives each individual in the population an equal chance of being included in the sample. Random...
11.3K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
996
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K